Celularity

Historical price data

Celularity is a vertically integrated cell therapy company with a mission to harness the postpartum placenta to create scalable, off-the-shelf cellular medicines. Its achievements include a robust, GMP-capable manufacturing facility, a diverse pipeline of placental-derived cell therapies and biomaterials, and strategic financial moves to bolster its longevity-focused strategy. The company's core strategy is to overcome the traditional barriers of cell therapy—scale, cost, and patient-specific manufacturing—by utilizing a readily available, ethically non-controversial biological source.

A proprietary platform that utilizes the postpartum placenta as a source to generate off-the-shelf, allogeneic cell therapies (including NK cells, T cells, and MLASCs) and advanced biomaterials, with integrated GMP manufacturing for scalability.

Celularity competes with numerous public cell therapy firms (e.g., Fate Therapeutics, Nkarta, Allogene) developing allogeneic platforms. Its differentiation is vertical integration and a placental source, but it faces the challenge of proving clinical and cost advantages against both novel modalities and its commercial biomaterial competitors in the wound care space.